Literature DB >> 21243006

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.

L R Brunham1, P J Lansberg, L Zhang, F Miao, C Carter, G K Hovingh, H Visscher, J W Jukema, A F Stalenhoef, C J D Ross, B C Carleton, J J P Kastelein, M R Hayden.   

Abstract

Statins reduce cardiovascular morbidity and mortality in appropriately selected patients. However, statin-associated myopathy is a significant risk associated with these agents. Recently, variation in the SLCO1B1 gene was reported to predict simvastatin-associated myopathy. The aim of this study was to replicate association of the rs4149056 variant in SLCO1B1 with severe statin-associated myopathy in a cohort of patients using a variety of statin medications and to investigate the association with specific statin types. We identified 25 cases of severe statin-associated myopathy and 84 controls matched for age, gender, statin type and dose. The rs4149056 variant in SLCO1B1 was not significantly associated with myopathy in this group as a whole. However, when subjects were stratified by statin type, the SLCO1B1 rs4149056 genotype was significantly associated with myopathy in patients who received simvastatin, but not in patients who received atorvastatin. Our findings provide further support for a role for SLCO1B1 genotype in simvastatin-associated myopathy, and suggest that this association may be stronger for simvastatin compared with atorvastatin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21243006     DOI: 10.1038/tpj.2010.92

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  66 in total

1.  Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives.

Authors:  Karin Hedenmalm; Arzu Gunes Granberg; Marja-Liisa Dahl
Journal:  Eur J Clin Pharmacol       Date:  2014-11-01       Impact factor: 2.953

Review 2.  Personalized vascular medicine: individualizing drug therapy.

Authors:  Emil M Degoma; Giovanni Rivera; Scott M Lilly; M Haris U Usman; Emile R Mohler
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

Review 3.  Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.

Authors:  John D Clarke; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-01-27       Impact factor: 4.481

Review 4.  Genetics and personalized medicine--a role in statin therapy?

Authors:  Jaideep Patel; Thura Abd; Roger S Blumenthal; Khurram Nasir; H Robert Superko
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

5.  SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.

Authors:  Paulo Caleb Junior Lima Santos; Ana Carolina Moron Gagliardi; Márcio Hiroshi Miname; Ana Paula Chacra; Raul Dias Santos; Jose Eduardo Krieger; Alexandre Costa Pereira
Journal:  Eur J Clin Pharmacol       Date:  2011-09-18       Impact factor: 2.953

6.  Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.

Authors:  Liam R Brunham; Steven Baker; Andrew Mammen; G B John Mancini; Robert S Rosenson
Journal:  Cardiovasc Res       Date:  2018-07-01       Impact factor: 10.787

7.  Genealogical analysis as a new approach for the investigation of drug intolerance heritability.

Authors:  Marc Tremblay; Tarek Bouhali; Daniel Gaudet; Diane Brisson
Journal:  Eur J Hum Genet       Date:  2013-11-27       Impact factor: 4.246

8.  [Pharmacogenomic Biomarkers for the Prediction of Statin Efficacy and Safety].

Authors:  Damiano Baldassarre; Mauro Amato; Beatrice Frigerio; Gualtiero Columbo; Philip F Binkley; Saurabh R Pandey; Adam M Suhy; Katherine Hartmann; Joseph P Kitzmiller
Journal:  G Ital Arterioscler       Date:  2013-11

Review 9.  The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations.

Authors:  Allyson M Schweitzer; Molly A Gingrich; Thomas J Hawke; Irena A Rebalka
Journal:  Eur J Appl Physiol       Date:  2020-04-04       Impact factor: 3.078

10.  Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver.

Authors:  Amy Webb; Audrey C Papp; Jonathan C Sanford; Kun Huang; Jeffrey D Parvin; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2013-05       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.